Nplus1 Singer Capital Markets Ltd Form 8.5 (EPT/RI) - Source Bioscience Plc (4375E)
July 18 2016 - 4:36AM
UK Regulatory
TIDMSBS
RNS Number : 4375E
Nplus1 Singer Capital Markets Ltd
18 July 2016
FORM 8.5 (EPT/RI)
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH
RECOGNISED IN,TERMEDIARY STATUS DEALING IN A CLIENT-SERVING
CAPACITY
Rule 8.5 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Name of exempt principal trader: Nplus1 Singer Capital Markets Limited
------------------------------------------------------------------------------ --------------------------------------
(b) Name of offeror/offeree in relation to whose relevant securities this
form relates: Source Bioscience Plc
Use a separate form for each offeror/offeree
------------------------------------------------------------------------------ --------------------------------------
(c) Name of the party to the offer with which exempt principal trader is
connected: Source Bioscience Plc
------------------------------------------------------------------------------ --------------------------------------
(d) Date dealing undertaken: 15 July 2016
------------------------------------------------------------------------------ --------------------------------------
(e) Has the EPT previously disclosed, or is it today disclosing, under the Yes
Code in respect
of any other party to this offer?
------------------------------------------------------------------------------ --------------------------------------
2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER
(a) Purchases and sales
Class of relevant Purchases/ sales Total number of Highest price per Lowest price per unit
security securities unit paid/received paid/received
------------------------ ------------------ ----------------------- ---------------------- -----------------------
ORD 2P Purchase 135,046 17.625p 17.625p
------------------------ ------------------ ----------------------- ---------------------- -----------------------
(b) Derivatives transactions (other than options)
Class of relevant Product description Nature of dealing Number of reference Price per unit
security e.g. CFD e.g. opening/closing a securities
long/short position,
increasing/reducing a
long/short position
------------------------- -------------------- ------------------------- ------------------------- ---------------
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
Class of Product Writing, Number of Exercise Type Expiry date Option money
relevant description purchasing, securities price per e.g. paid/
security e.g. call selling, to which unit American, received per
option varying etc. option European unit
relates etc.
------------- ------------- ------------- ------------- -------------- ------------- ------------ -------------
(ii) Exercising
Class of relevant security Product description Number of securities Exercise price per unit
e.g. call option
--------------------------- -------------------- --------------------- ------------------------
(d) Other dealings (including subscribing for new securities)
Class of relevant security Nature of dealing Details Price per unit (if applicable)
e.g. subscription, conversion
--------------------------- ------------------------------- -------- -------------------------------
The currency of all prices and other monetary amounts should be
stated.
Where there have been dealings in more than one class of
relevant securities of the offeror or offeree named in 1(b), copy
table 2(a), (b), (c) or (d) (as appropriate) for each additional
class of relevant security dealt in.
3. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal
or informal, relating to relevant securities which may be an inducement to deal or refrain
from dealing entered into by the exempt principal trader making the disclosure and any party
to the offer or any person acting in concert with a party to the offer:
If there are no such agreements, arrangements or understandings, state "none"
----------------------------------------------------------------------------------------------
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the exempt
principal trader making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which
any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
-----------------------------------------------------------------------------------------------
Date of disclosure: 18 July 2016
--------------------- --------------
Contact name: Reema Maru
--------------------- --------------
Telephone number: 020 7496 3094
--------------------- --------------
Public disclosures under Rule 8 of the Code must be made to a
Regulatory Information Service and must also be emailed to the
Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market
Surveillance Unit is available for consultation in relation to the
Code's dealing disclosure requirements on +44 (0)20 7638 0129. The
Code can be viewed on the Panel's website at
www.thetakeoverpanel.org.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
FERUWOWRNVABARR
(END) Dow Jones Newswires
July 18, 2016 04:36 ET (08:36 GMT)
Source Bioscience (LSE:SBS)
Historical Stock Chart
From Oct 2024 to Nov 2024
Source Bioscience (LSE:SBS)
Historical Stock Chart
From Nov 2023 to Nov 2024
